# Human PILRA Protein

**Cat. No.** PRA-HM201

## Description

| | |
|---|---|
| **Source** | Recombinant Human PILRA Protein is expressed from HEK293 with hFc tag at the C-Terminus. |
| | It contains Gln20-Ala197. |
| **Accession** | Q9UKJ1-1 |
| **Molecular Weight** | The protein has a predicted MW of 47 kDa. Due to glycosylation, the protein migrates to 60-68 kDa based on Bis-Tris PAGE result. |
| **Endotoxin** | Less than 1EU per μg by the LAL method. |
| **Purity** | > 95% as determined by Bis-Tris PAGE |
| | > 95% as determined by HPLC |

## Formulation and Storage

| | |
|---|---|
| **Formulation** | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| **Reconstitution** | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| **Storage** | -20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |

## Background

Alzheimer's disease (AD) is a neurodegenerative disease characterized by a progressive decline in cognitive performance; Mild Cognitive Impairment (MCI) is instead an objective decline in cognitive performance that does not reach pathology. Paired immunoglobulin-like type 2 receptor alpha (PILRA) is a cell surface inhibitory receptor that was recently suggested to be involved in AD pathogenesis. In particular, the arginine-to-glycine substitution in position 78 (R78, rs1859788) was shown to be protective against AD.

## Assay Data

**Bis-Tris PAGE**




Human PILRA on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

**SEC-HPLC**

# Human PILRA Protein

**Cat. No.** PRA-HM201

## Assay Data




The purity of Human PILRA is greater than 95% as determined by SEC-HPLC.